Novo CEO on Ozempic, Wegovy Demand, Acquisition Strategy

The video discusses the Biden administration's announcement of the first ten prescription drugs subject to Medicare price negotiations, with speculation that Ozempic might be next. The speaker expresses concerns about potential price fixing and emphasizes the need for dialogue with Medicare. They highlight the declining prices and affordability issues for patients. The impact of potential price cuts on the US market is considered, along with the value of their medicines. Challenges in the European rollout of Wagovi due to high demand are addressed, as well as efforts to increase US supply. The video concludes with Novo's acquisition strategy to strengthen its pipeline.

Discuss the significance of the declining prices and the issue of rebates not being shared with patients.

What are the company's plans regarding the supply of Wagovi in the US market?

How does the company view its acquisition strategy in relation to its growth in the diabetes and obesity sectors?